Steven Cohen Avadel Pharmaceuticals PLC Call Options Transaction History
Point72 Asset Management, L.P.
- $39.3 Billion
- Q1 2024
Call Options
1 transactions
Others Institutions Holding AVDL
# of Institutions
132Shares Held
68.4MCall Options Held
1.01MPut Options Held
2.03M-
Janus Henderson Group PLC London, X012.9MShares$179 Million0.12% of portfolio
-
Rtw Investments, LP New York, NY8.8MShares$122 Million2.38% of portfolio
-
Polar Capital Holdings PLC London, X06.75MShares$93.8 Million0.71% of portfolio
-
Gendell Jeffrey L Greenwich, CT5.71MShares$79.3 Million3.76% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.97MShares$55.2 Million8.97% of portfolio
About AVADEL PHARMACEUTICALS PLC
- Ticker AVDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 60,581,300
- Market Cap $841M
- Description
- Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...